Major bleeding risk in anticoagulation
Total Score
Low risk of major bleeding (~1-2%). Anticoagulation generally safe.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.
Yasal Uyarı: Bu platformdaki klinik skorlamalar ve algoritmalar yalnızca sağlık profesyonellerini bilgilendirme amaçlıdır. Herhangi bir kesin tıbbi teşhis, tedavi veya klinik karar yerine geçemez. Nihai karar ve sorumluluk hastayı yatak başında değerlendiren hekime aittir.
The HAS-BLED score is a widely used clinical tool designed to assess the 1-year risk of major bleeding in patients with atrial fibrillation receiving oral anticoagulation. It assists clinicians in identifying modifiable bleeding risk factors and scheduling closer follow-ups for high-risk individuals.
A high HAS-BLED score (≥3) is NOT a contraindication to anticoagulation. The ischemic stroke risk usually outweighs the bleeding risk. The primary utility of this score is to identify and correct modifiable factors (e.g., uncontrolled hypertension, concomitant NSAID use, excessive alcohol intake).
Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093-1100.
Disclaimer: The clinical scoring and algorithms on this platform are intended strictly for professional informational purposes. They do not constitute a definitive medical diagnosis, treatment, or clinical decision. The final judgment and responsibility lie with the treating physician.
Use HAS-BLED alongside CHA2DS2-VASc in AF patients being considered for anticoagulation — the goal is net clinical benefit, not bleeding avoidance alone. A HAS-BLED score ≥ 3 does NOT contraindicate anticoagulation; it flags patients who need closer follow-up and whose modifiable risk factors (uncontrolled hypertension, labile INRs, concurrent NSAIDs/antiplatelet drugs, alcohol use) should be aggressively corrected before or during therapy. The ESC recommends HAS-BLED specifically as a tool to identify and address bleeding risks, not to withhold OAC in patients with clear stroke benefit.
The 'A' component (Abnormal renal/liver function) can score up to 2 points — 1 point for each. Chronic dialysis, renal transplantation, or serum creatinine > 2.26 mg/dL (200 μmol/L) counts for renal dysfunction; cirrhosis, bilirubin > 2× normal, or AST/ALT > 3× normal counts for liver dysfunction. The 'D' component also scores up to 2 points — antiplatelet/NSAID use (1 pt) plus alcohol ≥ 8 drinks/week (1 pt). Maximum possible score is therefore 9, not 7.
A HAS-BLED score ≥ 3 is often misread as a contraindication to anticoagulation. Evidence consistently shows that in most patients with AF and CHA2DS2-VASc ≥ 2, the absolute stroke risk reduction with OAC exceeds the absolute bleeding risk increase — even with HAS-BLED ≥ 3. The 'labile INR' criterion applies to warfarin patients only (time in therapeutic range < 60%); for patients on NOACs, this criterion is not applicable. Reassess HAS-BLED annually and whenever a patient's medication list or renal/liver function changes.
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Journal of the American College of Cardiology. 2011;57:173–180.